Compare CBAT & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBAT | PYPD |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.5M | 77.4M |
| IPO Year | 2006 | 2014 |
| Metric | CBAT | PYPD |
|---|---|---|
| Price | $0.98 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 249.9K | 41.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 533.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,614,609.00 | N/A |
| Revenue This Year | $16.06 | N/A |
| Revenue Next Year | $70.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $2.30 |
| 52 Week High | $1.25 | $5.12 |
| Indicator | CBAT | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 42.82 |
| Support Level | $0.83 | $4.01 |
| Resistance Level | $1.06 | $4.38 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 68.18 | 45.12 |
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.